China Isotope subsidiary’s drug application accepted, shareholders approve dividend

China Isotope & Radiation Corporation's subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., has achieved a significant milestone with the official acceptance of its investigational “Borofalan (10B) for Injection” by the National Medical Products Administration’s Center for Drug Evaluation (CDE). This Boron Neutron Capture Therapy (BNCT) boron drug IND application marks a breakthrough in China’s BNCT technology and is expected to provide a novel therapeutic option for challenging tumors.

Concurrently, shareholders of China Isotope & Radiation Corporation approved the appointment of a domestic auditor for 2025 and the proposed interim dividend for the six months ended June 30, 2025, at an Extraordinary General Meeting (EGM) held on October 17, 2025. The total dividend amounts to RMB25,813,904.43 (inclusive of tax), with RMB0.0807 per share (inclusive of tax).

The interim dividend will be paid in RMB to holders of Domestic Shares and in HKD to holders of H Shares by December 31, 2025. H-share holders will receive HKD0.0884 per share (inclusive of tax). The ex-dividend date is October 21, 2025, with the book close period running from October 23 to October 28, 2025, and the record date set for October 28, 2025.